BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9634700)

  • 1. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.
    Olson ST; Swanson R; Day D; Verhamme I; Kvassman J; Shore JD
    Biochemistry; 2001 Oct; 40(39):11742-56. PubMed ID: 11570875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
    Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
    J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.
    Wardell MR; Chang WS; Bruce D; Skinner R; Lesk AM; Carrell RW
    Biochemistry; 1997 Oct; 36(42):13133-42. PubMed ID: 9335576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites.
    Fa M; Bergström F; Hägglöf P; Wilczynska M; Johansson LB; Ny T
    Structure; 2000 Apr; 8(4):397-405. PubMed ID: 10801484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms.
    Fa M; Bergström F; Karolin J; Johansson LB; Ny T
    Eur J Biochem; 2000 Jun; 267(12):3729-34. PubMed ID: 10848991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of plasminogen activator inhibitor-1.
    Wind T; Jensen JK; Dupont DM; Kulig P; Andreasen PA
    Eur J Biochem; 2003 Apr; 270(8):1680-8. PubMed ID: 12694181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.
    Hansen M; Busse MN; Andreasen PA
    Eur J Biochem; 2001 Dec; 268(23):6274-83. PubMed ID: 11733024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A.
    Kvassman JO; Lawrence DA; Shore JD
    J Biol Chem; 1995 Nov; 270(46):27942-7. PubMed ID: 7499270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.
    Sharp AM; Stein PE; Pannu NS; Carrell RW; Berkenpas MB; Ginsburg D; Lawrence DA; Read RJ
    Structure; 1999 Feb; 7(2):111-8. PubMed ID: 10368279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases.
    Aertgeerts K; De Ranter CJ; Booth NA; Declerck PJ
    J Struct Biol; 1997 Apr; 118(3):236-42. PubMed ID: 9169233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein conformational change delayed by steric hindrance from an N-linked glycan.
    Bager R; Johansen JS; Jensen JK; Stensballe A; Jendroszek A; Buxbom L; Sørensen HP; Andreasen PA
    J Mol Biol; 2013 Aug; 425(16):2867-77. PubMed ID: 23702291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved.
    Jendroszek A; Sønnichsen MS; Muñoz AC; Leyman K; Christensen A; Petersen SV; Wang T; Bendixen C; Panitz F; Andreasen PA; Jensen JK
    Thromb Haemost; 2017 Aug; 117(9):1688-1699. PubMed ID: 28771275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.
    Shore JD; Day DE; Francis-Chmura AM; Verhamme I; Kvassman J; Lawrence DA; Ginsburg D
    J Biol Chem; 1995 Mar; 270(10):5395-8. PubMed ID: 7890653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R; Petersen TE; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.